ASCO 2025 | OPTIMAL: oral vs IV paclitaxel in HER2-negative, chemo-naive metastatic breast cancer

Sung-Bae Kim • 30 May 2025

ASCO 2025

Breast Cancer Paclitaxel

OPTIMAL

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, comments on the Phase III OPTIMAL trial (NCT03315364), which evaluated oral versus intravenous (IV) paclitaxel in the management of HER2-negative chemotherapy-naive metastatic breast cancer. Prof. Kim highlights that the study’s primary endpoint of progression-free survival (PFS) was met, and the secondary endpoint of overall survival (OS) was also comparable. This suggests that oral paclitaxel could be a viable alternative to IV paclitaxel in this patient population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.